Compare JCSE & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JCSE | CDIO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | 17 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 5.4M |
| IPO Year | 2022 | N/A |
| Metric | JCSE | CDIO |
|---|---|---|
| Price | $1.33 | $1.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.7K | ★ 33.3K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $171,906.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.97 |
| 52 Week High | $2.50 | $7.91 |
| Indicator | JCSE | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 40.93 |
| Support Level | $1.02 | $1.68 |
| Resistance Level | $1.31 | $2.16 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 33.33 | 14.55 |
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company has two operating segments namely sale of cleaning systems and other equipment and provision of centralized dishware washing and general cleaning services. Geographically, the company derives a majority of its revenue from Singapore.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.